Haemonetics Corporation Common Stock (HAE)
Stock · NYSE · Health Care
$118.28as of 10/16/2026
Price chart
Active signals
HAE Signal Track Record
How signals performed across all stocks →What HAE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | +3.0% | 53% | October 8, 2026 |
| Bollinger Band Breakout | 23 | +0.6% | 57% | October 8, 2026 |
| Bollinger Band Breakdown | 19 | -2.3% | 42% | May 4, 2026 |
| 200-Day Moving Average TouchActive now | 18 | -0.8% | 50% | May 21, 2026 |
| Any 20-session window (baseline) | +0.5% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HAE
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information tec…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 3,009
- Website
- www.haemonetics.com
Fundamentals
- 1-day range
- $116.52$121.19
- Market cap
- $3.86B
- P/E (trailing)
- 56.08
- P/E (forward)
- 20.40
- EPS (trailing)
- $2.05
- Dividend yield
- —
- Beta
- 0.63
- Avg. volume
- 728.1K
How Haemonetics Corporation Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed May 20, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Haemonetics Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- HAEHaemonetics Corporation Common Stock$118.28▼ 2.48%Market cap $3.86BP/E 56.08$48.17$121.19
- ICUIICU Medical Inc. Common Stock$162.99▼ 2.54%Market cap $4.16BP/E 135.90$113.37$192.85
- IRTCiRhythm Holdings Inc. Common Stock$108.66▼ 0.63%Market cap $4.21BP/E —$100.7$212
- NVSTEnvista Holdings Corporation Common Stock$22.9▼ 2.55%Market cap $4.46BP/E 39.56$18.77$30.42
- PLSEPulse Biosciences Inc Common Stock (DE)$44.43▼ 2.54%Market cap $2.65BP/E —$12.56$58.9
- XRAYDENTSPLY SIRONA Inc. Common Stock$8.57▼ 2.94%Market cap $2.64BP/E —$8.38$14.76
- MMEDMiniMed Group Inc. Common Stock$17.49▼ 2.83%Market cap $5.17BP/E —$10.65$24.43
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HAE Haemonetics Corporation Common Stock | $3.86B | 56.08 | $118.28 | ▼ 2.48% | $48.17$121.19 |
| ICUI ICU Medical Inc. Common Stock | $4.16B | 135.90 | $162.99 | ▼ 2.54% | $113.37$192.85 |
| IRTC iRhythm Holdings Inc. Common Stock | $4.21B | — | $108.66 | ▼ 0.63% | $100.7$212 |
| NVST Envista Holdings Corporation Common Stock | $4.46B | 39.56 | $22.9 | ▼ 2.55% | $18.77$30.42 |
| PLSE Pulse Biosciences Inc Common Stock (DE) | $2.65B | — | $44.43 | ▼ 2.54% | $12.56$58.9 |
| XRAY DENTSPLY SIRONA Inc. Common Stock | $2.64B | — | $8.57 | ▼ 2.94% | $8.38$14.76 |
| MMED MiniMed Group Inc. Common Stock | $5.17B | — | $17.49 | ▼ 2.83% | $10.65$24.43 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140Benzinga · 10/9/2026
- Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140Benzinga · 10/9/2026
- Haemonetics: CSL Plasma Improves The Outlook, Not The Entry Point (Rating Downgrade)SeekingAlpha · 10/9/2026
- Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?Yahoo · 10/9/2026
- 3 Cash-Producing Stocks Walking a Fine LineYahoo · 10/9/2026
- Haemonetics (HAE) Jumped, What Is Behind The Move?Yahoo · 10/9/2026
- Stock Market Today: Nasdaq Slumps On War Worries; Oils Surges As Chevron Gains (Live Coverage)Yahoo · 10/8/2026
- Top stock movements in today's session.ChartMill · 10/8/2026
Insider Activity
Insider Actions →- Lloyd Emerson Johnson · July 24, 2026 · Grant2.5K
- Diane M. Bryant · July 24, 2026 · Grant2.5K
- Claire Pomeroy · July 24, 2026 · Grant2.5K
- Ellen M. Zane · July 24, 2026 · Grant2.5K
- Martin D. Madaus · July 24, 2026 · Grant2.5K
- Mark W. Kroll · July 24, 2026 · Grant2.5K
- Michael J. Coyle · July 24, 2026 · Grant2.5K
- Robert E. Abernathy · July 24, 2026 · Grant2.5K
- Farris Maryanne Maunsell · June 5, 2026 · Tax Withholding259 @ $71.28
- Laurie A. Miller · June 5, 2026 · Tax Withholding313 @ $71.28
- Frank Chan · May 15, 2026 · Grant27.5K
- Frank Chan · May 15, 2026 · Tax Withholding546 @ $56.29
- Farris Maryanne Maunsell · May 15, 2026 · Grant2.2K
- Farris Maryanne Maunsell · May 15, 2026 · Tax Withholding197 @ $56.29
- Roy Galvin · May 15, 2026 · Grant27.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 44.22M
- Total value held
- $2.40B
- Institutional holders
- 315
- Unknown5.62M
- Unknown3.56M
- Unknown3.36M
- Unknown2.09M
- Unknown1.77M
- Unknown1.38M
- Unknown1.33M
- Unknown1.33M
- Unknown1.28M
- Unknown1.22M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump
Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.